Markers of coagulation and platelet activation during percutaneous mitral valvuloplasty

Blood Coagulation and Fibrinolysis

Volumn 9, Issue 7, 1998, Pages 581-585

  Fernandez M A ^a   Villa, P ^a   Espana F ^a   Aznar, J ^a   Rincon De Arellano A ^a   Cebolla, R ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

F1+21; Markers of coagulation; Percutaneous mitral valvuloplasty; Platelet activation; TAT

Indexed keywords

ANTITHROMBIN III; THROMBIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMOSTASIS; HEPARINIZATION; HUMAN; MALE; MITRAL VALVE REPLACEMENT; MITRAL VALVE STENOSIS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION;

EID: 0031743567     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199810000-00003     Document Type: Article

References (27)

1. Inoue K, Owaki T, Nakamura T, Kitamura F, Miyamoyo N. Clinical application of transvenous mitral commissurotomy by a new balloon catheter. J Thorac Cardiovasc Surg 1984; 87: 394-402.
2. Zaibag M, Kasab S, Ribeiro PA, Fagih MR. Percutaneous double-balloon mitral valvotomy for rheumatic mitral valve stenosis. Lancet 1986; April 5; 757-761.
3. McKay CR, Kawanishi DT, Rahimtoola SH. Catheter balloon valvuloplasty of the mitral valve in adults using a double-balloon technique. JAMA 1987; 257: 1753-1761.
4. Palacios I, Block PC, Brandi S, Blanco P, Casal H, Pulido JI, et al. Percutaneous balloon valvulotomy for patients with severe mitral stenosis. Circulation 1987; 75: 778-784.
5. Winkins GT, Weyman AE, Abascal VM, Blockj PC, Palacios I. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J 1988; 60: 299-308.
6. Vahanian A, Michel PL, Cormier B, Vitoux B, Michel X, Slama M, et al. Results of percutaneous mitral commissurotomy in 200 patients. Am J Cardiol 1989; 63: 847-852.
7. Patel JJ, Shama D, Mitha AS, Blyth D, Hassen F, Le Roux BT. Balloon valvuloplasty vs. closed commissurotomy for pliable mitral stenosis: A prospective hemodynamic study. J Am Coll Cardiol 1991; 18: 1318-1322.
8. Reyes VP, Raju BS, Wynne J, Stephenson LW, Raju R, Fromm BS, et al. Percutaneous balloon valvuloplasty compared with open surgical commissurotomy for mitral stenosis. N Engl J Med 1994; 331: 961-967.
9. Dana CA. Use of transoesophageal echocardiography to detect left atrial thrombi before percutaneous balloon dilatation of the mitral valve: a prospective study. Br J Heart 1992; 67: 170-173.
10. Drobinski G, Montalescot G, Evans J, Nivet M, Thomas D, Grosgogeat Y. Systemic embolism as a complication of percutaneous mitral valvuloplasty. Catheter Cardiovasc Diag 1992; 25: 327-330.
11. Lee KS, Tuzcu EM, Elliot JM, Griffin BP. Development of left atrial thrombus following attempted percutaneous mitral valvuloplasty. Catheter Cardiovasc Diag 1994; 33: 345-348.
12. España F, Vicente V, Tabernero D, Scharrer I, Griffin JH. Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. Thromb Res 1990; 59: 593-608.
13. Villa P, Martínez M, Aznar J, Gilsanz A, Romar A. Potential usefulness of a modified prothrombin time for detecting plasma hypercoagulability. Thromb Haemorrh Disorders 1993; 7: 51-56.
14. Kataoke H, Yano S, Tamura A, Mikuriya Y. Hemostatic changes induced by percutaneous mitral valvuloplasty. Am Heart J 1993; 125: 777-782.
15. Takano K, Lino K, Ibayashi S, Tagawa K, Sadoshima S, Fujishima M. Hypercoagulable state under low-intensity warfarin anticoagulation assessed with hemostatic markers in cardiac disorders. Am J Cardiol 1994; 74: 935-939.
16. Boisclair MD, Lane DA, Philippou H, Sheikh S, Hunt B. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1+2. Thromb Haemost 1993; 70: 253-258.
17. Øvrum E, Holen EA, Tangen G, Brosstad F, Abdelnoor M, Ringdal MAL, et al. Completely heparinized cardiopulmonary bypass and reduced systemic heparin. Clinical and hemostatic effects. Ann Thorac Surg 1995; 60: 365-371.
18. Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant? Thromb Haemost 1993; 70: 263-265.
19. Vila V, Regañón E, Aznar J, Lacueva V, Ruano M, Laiz B. Hypercoagulable state after thrombolytic therapy in patients with acute myocardial infarction (AMI) treated with streptokinase. Thromb Res 1990; 57: 783-794.
20. España F, Vicente V, Vazquez L, Estellés A, Sánchez-Cuenca J, Aznar J. Complex formation between protein C inhibitor and tissue plasminogen activator during thrombolytic therapy. Evidence of activation of protein C pathway. Fibrinolysis 1993; 7: 308-315.
21. Galvani M, Abendschein DR, Ferrini D, Ottani F, Rusticalli F, Eisenberg PR. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase. J Am Coll Cardiol 1994; 24: 1445-1452.
22. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Spinola A, Cattaneo M, et al. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1995; 25: 203-209.
23. Hynes TM, Hull R, Weg JG. Antithrombotic therapy of venous thromboembolism disease. Chest 1986; 89: 26S-35S.
24. Vicente V, España F, Tabernero D, Estellés A, Aznar J, Hendl S, et al. Evidence of activation of the protein C pathway during acute vascular damage induced by Mediterranean spotted fever. Blood 1991; 78: 416-422.
25. 1AT) complex as a marker for in vitro diagnosis of prethrombotic states. Thromb Res 1992; 66: 499-508.
26. Schwartz L, Seidelin PH. Antithrombotic and thrombolytic therapy in patients undergoing coronary artery interventions: a review. Prog Cardiovasc Dis 1995; 38: 67-86.
27. Altman R, Boulon F, Rouvier J. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg 1976; 72: 127-129.